Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Susceptibility to ankylosing spondylitis (AS) is polygenic with more than 100 genes identified to date. These include HLA-B27 and the aminopeptidases (ERAP1, ERAP2, and LNPEPS), which are involved in antigen processing and presentation to T-cells, and several genes (IL23R, IL6R, STAT3, JAK2, IL1R1/2, IL12B, and IL7R) involved in IL23 driven pathways of inflammation. AS is also strongly associated with polymorphisms in two transcription factors, RUNX3 and T-bet (encoded by TBX21), which are important in T-cell development and function. The influence of these genes on the pathogenesis of AS and their potential for identifying drug targets is discussed here.

Original publication




Journal article


Front Immunol

Publication Date





ankylosing spondylitis, autoimmunity, functional genomics, inflammation, therapy, Aminopeptidases, CD8-Positive T-Lymphocytes, Core Binding Factor Alpha 3 Subunit, Gene Expression Regulation, HLA-B27 Antigen, Humans, Immunologic Factors, Interleukin-23, Killer Cells, Natural, Molecular Targeted Therapy, Polymorphism, Single Nucleotide, Receptors, Interleukin, Spondylitis, Ankylosing, T-Box Domain Proteins